Stock Track | 3SBio Soars 5.05% Intraday on Strong 2025 Earnings and Undervaluation Appeal

Stock Track04-13

3SBio's stock price surged 5.05% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.

The sharp rise appears driven by the company's recently reported strong financial performance for 2025, which included sales of CNY 17,695.75 million and net income of CNY 8,482.16 million. Investors also responded positively to the company's reaffirmed final dividend, highlighting a commitment to returning cash to shareholders. Analyst commentary further supported the move, noting the stock trades at a P/E ratio of just 5.9x, which is considered undervalued compared to an estimated fair P/E of 10.4x and significantly below industry peer averages.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125668655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 13:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125668655","market":"hk","top_or_hot":-1,"title":"Stock Track | 3SBio Soars 5.05% Intraday on Strong 2025 Earnings and Undervaluation Appeal","media":"Stock Track","content":"<p>3SBio's stock price surged 5.05% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by the company's recently reported strong financial performance for 2025, which included sales of CNY 17,695.75 million and net income of CNY 8,482.16 million. Investors also responded positively to the company's reaffirmed final dividend, highlighting a commitment to returning cash to shareholders. Analyst commentary further supported the move, noting the stock trades at a P/E ratio of just 5.9x, which is considered undervalued compared to an estimated fair P/E of 10.4x and significantly below industry peer averages.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBio Soars 5.05% Intraday on Strong 2025 Earnings and Undervaluation Appeal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBio Soars 5.05% Intraday on Strong 2025 Earnings and Undervaluation Appeal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-13 13:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBio's stock price surged 5.05% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by the company's recently reported strong financial performance for 2025, which included sales of CNY 17,695.75 million and net income of CNY 8,482.16 million. Investors also responded positively to the company's reaffirmed final dividend, highlighting a commitment to returning cash to shareholders. Analyst commentary further supported the move, noting the stock trades at a P/E ratio of just 5.9x, which is considered undervalued compared to an estimated fair P/E of 10.4x and significantly below industry peer averages.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1125668655","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125668655","pubTimestamp":1776058472,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBio's stock price surged 5.05% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by the company's recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|三生制药盘中大涨5.05%2025年盈利强劲且具有低估值吸引力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBio's stock price surged 5.05% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by the company's recently reported strong financial performance for 2025, which included sales of CNY 17,695.75 million and net income of CNY 8,482.16 million. Investors also responded positively to the company's reaffirmed final dividend, highlighting a commitment to returning cash to shareholders. Analyst commentary further supported the move, noting the stock trades at a P/E ratio of just 5.9x, which is considered undervalued compared to an estimated fair P/E of 10.4x and significantly below industry peer averages.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125668655","isCrawlerRequest":true}